---
layout: default
title: Mephenesin
parent: 僅模型預測 (L5)
nav_order: 416
evidence_level: L5
indication_count: 10
---

# Mephenesin
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Mephenesin: From Muscle Relaxant to Metastatic Melanoma

## One-Sentence Summary

Mephenesin is a first-generation central nervous system depressant historically used as a muscle relaxant, acting on spinal polysynaptic reflex arcs via glycinergic/GABAergic interneurons.
The TxGNN model predicts it may be effective for **Metastatic Melanoma**,
with **0 clinical trials** and **0 publications** currently supporting this direction — making this a pure model-driven hypothesis at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Muscle relaxant (CNS depressant; spinal polysynaptic reflex inhibition) |
| Predicted New Indication | Metastatic Melanoma |
| TxGNN Prediction Score | 96.26% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, Mephenesin is a first-generation centrally acting muscle relaxant that exerts its effect by inhibiting polysynaptic reflexes in the spinal cord, primarily through GABAergic and glycinergic interneuron pathways. Its clinical use largely predates modern drug approval standards, and it has since been superseded by newer agents.

The theoretical bridge between Mephenesin and melanoma rests on an interesting biological observation: melanocytes — and by extension melanoma cells — originate from the neural crest, a transient embryonic structure that gives rise to components of the peripheral nervous system. Some neurotransmitter receptors (including GABA-related proteins) have been documented to be ectopically expressed in neural crest-derived tumour cells. The TxGNN knowledge graph may have detected a connection via shared GABAergic protein nodes or oxidative stress pathway intersections.

However, this mechanistic link is **highly speculative**. There is no published preclinical or clinical evidence connecting Mephenesin to any melanoma subtype. The prediction likely reflects the model's sensitivity to neural crest biology rather than a pharmacologically validated interaction. The identical TxGNN scores observed across multiple cataract subtypes (ranks 5–9) further suggest that a portion of these top predictions arise from knowledge graph clustering artefacts rather than genuine biological signals.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Mephenesin currently has **no registered products** in India. The drug is not marketed and has no active licences on record.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model assigns a high score (96.26%) to the Mephenesin–metastatic melanoma pairing, but this is based entirely on knowledge graph topology with no supporting clinical trials, observational studies, or published literature (Evidence Level L5). Combined with the complete absence of India market presence, missing MOA data, and a mechanistic hypothesis that remains highly inferential, there is insufficient basis to advance this candidate.

**To proceed, the following is needed:**

- **MOA characterisation**: Retrieve and document Mephenesin's full mechanism of action from DrugBank or primary literature to assess whether any molecular target overlaps with melanoma biology
- **Preclinical signal search**: Conduct a broad PubMed search for Mephenesin + cancer / GABA + melanoma / neural crest + muscle relaxant to determine if any preclinical signals exist outside the queried scope
- **KG artefact review**: Investigate whether the shared identical scores across cataract subtypes (ranks 5–9) indicate a graph clustering issue that may also affect the melanoma predictions; if confirmed, adjust confidence accordingly
- **Safety data retrieval**: Download and parse the original product monograph or SmPC to populate the missing warnings and contraindications before any further evaluation
- **Regulatory feasibility check**: Since Mephenesin is not marketed in India, assess regulatory pathway requirements (new drug application vs. repurposing submission) before committing research resources

> ⚠️ **Disclaimer**: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

